Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 13/20 | 0.65 |
| ▸ | CES1 | P23141 | 12/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5859663 | 0.91 | PLK1 (0.61) | CES2CES1RAB9APLK1ALDH1A1 | |
| SCHEMBL2149065 | 0.87 | ALDH1A1 (0.61) | CES2CES1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL14199625 | 0.87 | AKR1C3 (0.49) | CES2CES1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15127802 | 0.87 | AKR1C3 (0.49) | CES2CES1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL10110528 | 0.84 | PLK1 (0.55) | CES2CES1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL31626728 | 0.83 | ALDH1A1 (0.46) | CES2CES1AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7089334 | 0.83 | CES2 (0.70) | CES2CES1RAB9APLK1ALDH1A1 | |
| SCHEMBL11311150 | 0.82 | CES2 (0.71) | CES2CES1RAB9AALDH1A1HPGD | |
| SCHEMBL7575160 | 0.82 | NR4A2 (0.59) | CES1AKR1C3AKR1C2AKR1C1RAB9A | |
| SCHEMBL11680326 | 0.82 | AKR1C3 (0.51) | CES2CES1AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0949540-B1 | Method for producing lithographic printing plate suitable for laser scan exposure, and photopolymerizable composition | FUJIFILM CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| US-4008232-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3979516-A | Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines | ELI LILLY AND COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3948894-A | ANTIINFLAMMATORY | ELI LILLY AND COMPANY (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | CES2 984/4885CES1 374/4885AKR1C3 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.